Diamyd Medical AB

Diamyd Medical AB
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

Diamyd Medical develops precision medicine therapies for the prevention and treatment of autoimmune diabetes. The investigational flagship product Diamyd® is a disease-modifying antigen-specific immunotherapy for the preservation of endogenous insulin production that has Orphan Drug Designation in the U.S. and has been granted Fast Track designation by the U.S. FDA. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset Type 1 Diabetes in eight European countries and in the U.S.

Contacts

Ulf Hannelius

CEO

Box 7349, SE-103 90 Stockholm
+46 8 661 00 26
https://www.diamyd.com
press@diamyd.com

Links

Diamyd Medcial

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Diamyd Medical announces governance and leadership update

Fri, Apr 24, 2026 10:30 CET

Further to the Company’s press release regarding governance changes following the March 27 interim analysis of its DIAGNODE-3 study, Diamyd Medical today announces that Chairman Anders Essen-Möller has been appointed Chief Executive Officer. Vice Chairman Erik Nerpin has been appointed Chairman of the Board. As previously announced, Ulf Hannelius has stepped down from his role as CEO and will remain in a supervisory capacity during his notice period to support the transition. About Diamyd MedicalDiamyd Medical develops precision medicine therapies to prevent and treat type 1 diabetes.

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Contacts

Links

Diamyd Medical announces governance and leadership update

Subscribe